Mirum Pharmaceuticals, Inc. (MIRM)
MIRM Stock Price Chart
Explore Mirum Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze MIRM price movements and trends.
MIRM Company Profile
Discover essential business fundamentals and corporate details for Mirum Pharmaceuticals, Inc. (MIRM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jul 2019
Employees
334.00
Website
https://www.mirumpharma.comCEO
Christopher Peetz
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
MIRM Financial Timeline
Browse a chronological timeline of Mirum Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.17.
Earnings released on 6 Aug 2025
EPS came in at -$0.12 surpassing the estimated -$0.31 by +61.29%, while revenue for the quarter reached $127.79M , missing expectations by -1.10%.
Earnings released on 7 May 2025
EPS came in at -$0.30 surpassing the estimated -$0.39 by +23.08%, while revenue for the quarter reached $111.59M , beating expectations by +13.40%.
Earnings released on 26 Feb 2025
EPS came in at -$0.49 falling short of the estimated -$0.27 by -81.48%, while revenue for the quarter reached $99.41M , beating expectations by +2.87%.
Earnings released on 12 Nov 2024
EPS came in at -$0.30 surpassing the estimated -$0.45 by +33.33%, while revenue for the quarter reached $90.38M , missing expectations by -5.31%.
Earnings released on 7 Aug 2024
EPS came in at -$0.52 falling short of the estimated -$0.48 by -8.33%, while revenue for the quarter reached $77.88M , beating expectations by +3.49%.
Earnings released on 8 May 2024
EPS came in at -$0.54 falling short of the estimated -$0.40 by -35.00%, while revenue for the quarter reached $69.22M , missing expectations by -1.35%.
Earnings released on 28 Feb 2024
EPS came in at -$0.66 falling short of the estimated -$0.34 by -94.12%, while revenue for the quarter reached $69.55M , beating expectations by +2.65%.
Earnings released on 2 Nov 2023
EPS came in at -$0.57 surpassing the estimated -$0.64 by +10.94%, while revenue for the quarter reached $47.73M , missing expectations by -30.09%.
Earnings released on 3 Aug 2023
EPS came in at -$0.92 falling short of the estimated -$0.81 by -13.58%, while revenue for the quarter reached $37.50M , beating expectations by +15.48%.
Earnings released on 4 May 2023
EPS came in at -$0.80 surpassing the estimated -$0.96 by +16.67%, while revenue for the quarter reached $31.60M , beating expectations by +10.14%.
Earnings released on 8 Mar 2023
EPS came in at -$0.99 falling short of the estimated -$0.98 by -1.02%, while revenue for the quarter reached $27.91M , beating expectations by +13.58%.
Earnings released on 9 Nov 2022
EPS came in at -$1.02 surpassing the estimated -$1.05 by +2.86%, while revenue for the quarter reached $18.78M , missing expectations by -9.75%.
Earnings released on 4 Aug 2022
EPS came in at -$0.84 surpassing the estimated -$1.05 by +20.00%, while revenue for the quarter reached $17.48M , beating expectations by +13.41%.
Earnings released on 5 May 2022
EPS came in at -$1.17 surpassing the estimated -$1.39 by +15.83%, while revenue for the quarter reached $12.89M , beating expectations by +52.33%.
Earnings released on 9 Mar 2022
EPS came in at -$0.92 falling short of the estimated -$0.61 by -50.82%, while revenue for the quarter reached $3.14M , missing expectations by -94.99%.
Earnings released on 15 Nov 2021
EPS came in at -$1.55 surpassing the estimated -$1.63 by +4.91%, while revenue for the quarter reached $5.00M , beating expectations by +502.41%.
Earnings released on 5 Aug 2021
EPS came in at -$1.45 falling short of the estimated -$0.41 by -253.66%, while revenue for the quarter reached $11.00M , missing expectations by -24.14%.
Earnings released on 6 May 2021
EPS came in at -$1.68 falling short of the estimated -$0.67 by -150.75%.
Earnings released on 9 Mar 2021
EPS came in at -$1.43 falling short of the estimated -$0.57 by -150.88%.
Earnings released on 12 Nov 2020
EPS came in at -$0.86 surpassing the estimated -$0.99 by +13.13%.
MIRM Stock Performance
Access detailed MIRM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.